Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-EVA1C nanobody
- Development stage
- Preclinical
- Lead developer
- Harvard Medical School
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The anti-EVA1C nanobody is an engineered camelid-derived single-domain antibody (nanobody) designed to target the ectodomain of protein eva-1 homolog C (EVA1C). EVA1C is a membrane protein identified as a potential microvascular biomarker robustly expressed on the luminal surface of endothelial cells in ectopic endometriosis (EM) lesions, but not in eutopic endometrium or other normal tissues. Developed by researchers at Harvard Medical School, the nanobody is being investigated for both non-invasive diagnostic imaging (when conjugated to a radiotracer or contrast agent) and targeted therapeutic delivery (when carrying a therapeutic payload) to localize, monitor, and ablate endometriosis lesions.
- Other names
- anti-EVA1C NAbanti-EVA-1C NAbanti-EVA 1C NAbanti-EvA1C nanobodyanti-EvA-1C nanobodyanti-EvA 1C nanobody
Beyond the preview
Go deeper on anti-EVA1C nanobody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-EVA1C nanobody.